<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657513</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2012-001</org_study_id>
    <secondary_id>H-2-2012-001</secondary_id>
    <nct_id>NCT01657513</nct_id>
  </id_info>
  <brief_title>TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis</brief_title>
  <official_title>Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Michaelsen Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TNF alfa blockers are widely used for treatment of severe psoriasis. These biologics are
      well-tolerated with few side effects.

      Unfortunately not all patients respond adequately to treatment with tnf alfa blockers. Some
      do not respond at all while others respond initially but gradually lose effect despite
      increased dose and more frequent administration.

      The cause of treatment failure is largely unknown and it may be production of tnf-alfa
      neutralizing antibodies. This has been demonstrated in patients with rheumatoid arthritis and
      inflammatory bowel disease who lost response after treatment with tnf-alfa blockers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in concentration of tnf-alfa antibodies in serum</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>Measurement (ELISA) of concentration of tnf-alfa neutralizing antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in severity of psoriasis, PASI</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>severity of psoriasis assessed by PASI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of psoriatic arthritis</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>Does the patient have psoriasis arthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in dermatology life quality index (DLQI)</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>psoriasis severity assessed by the dermatology life quality index (DLQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height (cm)</measure>
    <time_frame>3 months</time_frame>
    <description>subject´s height in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in weight (kg)</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>subjects weight in kilograms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>assessment of change in concentrations of other biomarkers of interest in psoriasis</measure>
    <time_frame>3, 6, and 12 months after start of tnf-alfa blocking agent</time_frame>
    <description>Collection of 3 ml of serum which are kept at -80 degrees celcius for later analysis of future biomarkers of interest</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>tnf-alfa treatment (infliximab, adalimumab, or etanercept)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm includes all the patients of the study. They are patients who are start treatment with a tnf-alfa blocking drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subjects will receive either infliximab, adalimumab or etanercept</intervention_name>
    <description>The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.
The study subjects will receive treatment with one drug only -
infliximab or
adalimumab or
etanercept
The consulting dermatologist decides which drug to use according to official guidelines</description>
    <arm_group_label>tnf-alfa treatment (infliximab, adalimumab, or etanercept)</arm_group_label>
    <other_name>infliximab</other_name>
    <other_name>adalimumab</other_name>
    <other_name>etanercept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Age above 18

          -  Psoriasis

          -  Indication for treatment with tnf alfa blocking drug

          -  Written informed consent obtained

        Exclusion Criteria:

          -  Severe psychiatric disorder

          -  No indication for treatment with tnf-alfa blocking drug

          -  Pregnancy

          -  Breastfeeding

          -  No written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lone Skov, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Copenhagen University Hospital Gentofte, Department of Skin and Allergies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Ståhle, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, Department of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lone Skov, MD, PhD</last_name>
    <phone>+4539773204</phone>
    <email>lone.skov.02@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Jensen, MD</last_name>
    <phone>+4539777538</phone>
    <email>peter.jensen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Copenhagen University Hospital Gentofte, Department of Skin and Allergies</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lone Skov, MD, PhD</last_name>
      <phone>+4539773204</phone>
      <email>lone.skov.02@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Peter Jensen, MD</last_name>
      <phone>+4539777538</phone>
      <email>peter.jensen@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Lone Skov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claus Zachariae, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Institute, Department of Medicine</name>
      <address>
        <city>Stockholm</city>
        <zip>17177</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Ståhle, MD, PhD</last_name>
      <email>mona.stahle@ki.dk</email>
    </contact>
    <investigator>
      <last_name>Mona Ståhle, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>August 3, 2012</last_update_submitted>
  <last_update_submitted_qc>August 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Jensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>treatment failure</keyword>
  <keyword>tnf-alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

